Analyst Research

Report Title Price
Provider: MarketLine (a Datamonitor Company)
$175.00
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$250.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Ipsen SA Announces Positive Top Line Results from Phase III ELECT Study of Somatuline in the Control of Symptoms in Net Patients with History of Carcinoid Syndrome


Tuesday, 17 Sep 2013 01:30am EDT 

Ipsen SA announced positive top line results from the primary endpoint of the ELECT study, assessing the effect of Somatuline Autogel / Somatuline Depot (lanreotide) Injection 120 milligrams (referred to as Somatuline) on the control of symptoms in patients with neuroendocrine tumors (NETs) associated with carcinoid syndrome. Treatment with Somatuline was found to be statistically significantly superior to placebo in decreasing the number of days patients needed to use rescue medication (subcutaneous somatostatin analogues i.e., octreotide) to control symptoms associated with carcinoid syndrome. The safety profile observed in the study is consistent with the known safety profile of Somatuline. The Company expects to present comprehensive results from this study in January 2014. 

Company Quote

31.935
-1.065 -3.23%
7:56am EDT